Skip to Main Content
Tim Springer

This billionaire has quietly driven Boston’s biotech industry for decades

July 29, 2022... “Tim is a weird-science guy." A 74-year-old professor at Harvard Medical School and a research lab chief at Boston Children’s Hospital is a heads-down scientist and entrepreneur with some notable quirks.

Noubar Afeyan

Flagship’s latest startup launches with bold claim: the discovery of thousands of new human proteins

May 26, 2022... A Cambridge, Mass., biotech company claims to have made a discovery that could rewrite biology textbooks.

Pharmalittle: Moderna chair defends executive hiring process; analysis finds monopoly tactics preserve inhaler revenues

May 18, 2022... Moderna chair Noubar Afeyan launched an unflinching defense of the board’s executive hiring process after it was forced to fire its new chief financial officer last week.

Noubar Afeyan

Feb. 9, 2022... Afeyan founded Flagship in 2000, building it into one of the world’s leading life science venture capital firms — often conceiving or incubating companies itself. Flagship has made numerous successful investments in recent years, among them Rubius Therapeutics, which bioengineers red blood cells to create new cellular therapies. But Flagship’s most notable success is Moderna,…

Flagship Pioneering’s Noubar Afeyan on the crazy idea behind Moderna and professional entrepreneurs

Nov. 21, 2021... Though “Moderna” is now used as a shorthand for a Covid-19 vaccine, developing vaccines was not originally in the company's game plan.

Pharmalittle: Most Americans support Medicare drug price negotiations; Moderna refuses to share its Covid-19 vaccine secret sauce

Oct. 12, 2021... A large majority of Americans support allowing the U.S. government to negotiate for Medicare drugs, a Kaiser Family Foundation poll shows.

STAT announces third annual 2021 STAT Summit

Sept. 30, 2021... 2021 STAT Summit will feature NIAID Director Dr. Anthony Fauci and Pfizer CEO Albert Bourla BOSTON, MA - Today, STAT, the nation’s must-read health, science, and medicine publication, announced its 2021 STAT Summit. The event will be hybrid from November 16-18, 2021, with programming taking place from 1:00 - 4:30 p.m. ET each day. The…

one hundred dollar bills

Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms

Aug. 23, 2021... A Flagship Pioneering fund reported a 15x investment multiple, the highest of any included in a new STAT report that looks at returns for 17 major biotech venture capital firms during the pandemic. 

STAT Summit 2021

2021 STAT Summit

July 13, 2021... nov 16-18hybrid event#statsummit View Highlights About Charting a course for medicine's future Leading figures in science and medicine joined us at the 2021 STAT Summit. Corporate executives, top scientists, patient advocates, and government officials had spirited discussions with each other, and with STAT’s award-winning reporters. They answered your questions and dove deep into the hottest…

FDA Nominee Stephen Hahn

Former FDA chief Hahn defends his jump to Flagship Pioneering, the firm behind Moderna

June 15, 2021... In an interview with STAT, Hahn said no one from Moderna played any part in his transition to Flagship Pioneering, the venture capital firm with close ties to the Covid-19 vaccine maker.

vaccine apartheid

If vaccine apartheid exists, vaccine billionaires shouldn’t

June 12, 2021... Founders and investors have been allowed to bend the course of the pandemic to their private benefit. When a few people win big, everyone else loses.

MODERNA - Norwood facility

Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents

May 7, 2021... Moderna chief executive Stephane Bancel shrugged off the Biden administration’s support for suspending patents for coronavirus vaccines.

VC funding

At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness

Feb. 16, 2021... Flagship Pioneering, the venture capital firm behind Moderna Therapeutics, has an internal culture to match its exterior image: brazen, unconventional, and incredibly demanding.

Pfizer freezer farm

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race

Nov. 10, 2020... The story of mRNA began is a tale of personal perseverance, eureka moments in the lab, soaring expectations — and an unprecedented flow of cash in biotech.

H-1B visa

Cutting off H-1B visas will hurt the biopharma industry

Oct. 6, 2020... Many international students who train in the U.S. want to stay here, rent or buy homes, dine at restaurants, shop at local stores, participate in our economy, become active members of the community, and even pay taxes, all while contributing to scientific discoveries with the potential to transform society — or at least they used…

Flag poles

A global pathogen shield: the health security step to ‘never again’

May 11, 2020... In the name of national security, the world's countries have amassed enough nuclear weapons to destroy human civilization, and they accept the massive financial investment. We need the same aggressive approach for health security.

money stack

Big biotech venture funds raise billions despite coronavirus fears

April 2, 2020... These are difficult times. But two of the top biotech venture firms just raised a total of $2.6 billion to fund new startups.

Adenovirus particles

Ring Therapeutics is developing a new way to deliver gene therapy

Dec. 19, 2019... “With Ring, we are truly forging new ground by pioneering an entirely new category of DNA medicines based on nature,” said Noubar Afeyan, founder and chief executive of Flagship.


And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!

Dec. 17, 2019... Here are @adamfeuerstein's nominees for worst biopharma CEO of 2019.

F*!@ Disease

A mysterious startup launched with an impossibly ambitious rallying cry. Now its plans are coming into focus

July 30, 2019... Sana Biotechnology's early code name, FD Therapeutics, hints at the buzzy startup's aggressive vision. Guess what it stands for.


Startup Spotlight: Flagship’s latest single-cell sequencing startup gets a name: Cellarity

May 20, 2019... One of Flagship Pioneering’s single-cell sequencing startups is inching out of stealth mode.

Rivers of funding

Biotech runs on venture capital. But not all VC models are created equal

May 3, 2019... In biotech, funding doesn’t just fall into scientists’ and entrepreneurs’ laps. @sheridan_kate explains how venture capital works.

Noubar Afeyan

Flagship Pioneering raises $824 million in venture capital round, its most ever

March 20, 2019... Since 2000, Flagship has raised a total of $3.3 billion to spawn and finance biotech, medical technology, and bio-agriculture businesses.

Robo Gut

A trip to ‘the poopy lab’ in the interest of drug development

Feb. 16, 2018... A University of Guelph scientist uses a mechanical colon she calls the "Robogut" to study the gut microbiome and produce "feces" for a clinical trial to treat C. difficile infections.

Noubar Afeyan

Flagship Pioneering raises $618 million more to bankroll life sciences startups

Dec. 21, 2017... The new venture round — Flagship’s largest one-time infusion ever — boosts to $2.3 billion the total capital raised by the firm since its founding in 2000.

Moderna sign

Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline

July 27, 2017... Moderna Therapeutics, a $5 billion startup that boasts of changing the world, is losing a key partner, imperiling its most advanced drug project.

Noubar Afeyan

Why does anyone care what venture capital firms are called?

Dec. 15, 2016... Venture capital firms are branding themselves with ever snazzier, snappier, more ahead-of-the-curve names. Our question: Why bother?


Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

Sept. 13, 2016... Moderna's caustic work environment has driven away top talent. There are signs the secretive startup has hit roadblocks with its most ambitious projects.

Katrine Bosley

4 people shaping Kendall Square’s future

May 6, 2016... Katrine Bosley has the biotech chops to help make medicines out of CRISPR gene-editing technology.